Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp in Moderate to Severe Chronic Periodontitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02325570
Recruitment Status : Completed
First Posted : December 25, 2014
Last Update Posted : February 23, 2016
Sponsor:
Information provided by (Responsible Party):
KLOX Technologies Inc.

Brief Summary:
Multicenter, prospective, interventional open case series study using a randomized split-mouth design in moderate to severe chronic periodontitis patients having half-mouth treated with the KLOX BioPhotonic OraLum gel with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP) versus SRP alone in the second (control) half-mouth.

Condition or disease Intervention/treatment Phase
Moderate to Severe Chronic Periodontitis Device: KLOX BioPhotonic OraLum Gel Procedure: Scaling and Root Planing (SRP) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Evaluation of the Clinical Effects of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp as an Adjunct to the Non-Surgical Treatment of Moderate to Severe Chronic Periodontitis
Study Start Date : November 2014
Actual Primary Completion Date : March 2015
Actual Study Completion Date : May 2015

Arm Intervention/treatment
Experimental: KLOX BioPhotonic OraLum Gel + SRP
Split-mouth design:the half-mouth randomly selected will be treated with KLOX BioPhotonic OraLum gel (with a LED curing lamp) as an adjunct to SRP.
Device: KLOX BioPhotonic OraLum Gel
Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).

Procedure: Scaling and Root Planing (SRP)
Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.

Scaling and Root Planing (SRP)
The second half-mouth will be treated with SRP alone.
Procedure: Scaling and Root Planing (SRP)
Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.




Primary Outcome Measures :
  1. Adverse events, Serious adverse events and incidents [ Time Frame: 3 weeks ]
    Number of patients with adverse events, serious adverse events and incidents

  2. Ease of performing SRP and time required to perform SRP [ Time Frame: 2 weeks ]

Secondary Outcome Measures :
  1. Impact on tissues (Visual examination of tissues) [ Time Frame: 3 weeks ]
    Visual examination of tissues

  2. Impact on bleeding (Use of Bleeding on Probing (BOP) results) [ Time Frame: 2 weeks ]
    Use of Bleeding on Probing (BOP) results

  3. Impact on Plaque Index (PI) [ Time Frame: 2 weeks ]
  4. Impact on Gingival index (GI) [ Time Frame: 2 weeks ]
  5. Pain (Visual Analog Scale) [ Time Frame: 2 weeks ]

Other Outcome Measures:
  1. Exploratory endpoint: patient's preference questionnaire [ Time Frame: 2 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed and dated written informed consent form;
  2. Male or female patients aged 18 years old and above;
  3. Good general health, free of systemic diseases such as diabetes, arthritis, HIV infection or genetic disorder that could influence the outcome of the treatment;
  4. Patient with clinically confirmed signs and symptoms of generalized moderate to severe chronic periodontitis (as defined according to International Classification of Periodontal Diseases, Armitage 1999);
  5. Patient has had no periodontal treatment for the last year prior to the study;
  6. Females of childbearing potential must not be pregnant nor lactating at study entry and agree to use an adequate contraceptive method during the study.

    Inclusion Criteria Post Oral Hygiene Instructions (OHI):

  7. Patient demonstrates sufficient plaque control as indicated by a plaque score < 30% after hygiene period;
  8. Patient has at least two sites in each quadrant with probing pocket depth (PPD) equal or more than 5 mm or equal or less than 7 mm.

Exclusion Criteria:

  1. Patient with an existing aggressive periodontitis;
  2. Presence of oral local mechanical factor(s) that could, in the opinion of the investigator, influence the outcome of the study;
  3. Presence of orthodontic appliances, or any removable appliances, that impinges on the tissues being assessed;
  4. Soft or hard tissue tumours of the oral cavity;
  5. Systemic antibiotic therapy or anti-inflammatory drugs or any other medication(s) that might interfere with periodontal healing within the last three months prior to study entry and throughout the study duration;
  6. Patient has participated in any other clinical study within 30 days prior to study entry and throughout the study duration;
  7. Use of anticoagulants such as warfarin, clopidogrel, enoxaparin or high doses of aspirin (162 mg daily);
  8. Regular use of chlorhexidine oral rinses / mouthwashes (Non-medicated, over the counter, mouthwashes are acceptable);
  9. Patient with current alcohol abuse or actively consuming drugs (addiction); as it may interfere with patient's ability to comply with study procedures
  10. Periodontal surgery planned during the study;
  11. Female patient pregnant, nursing or planning to become pregnant within the next 12 months;
  12. Patient is a current smoker or had been smoking or using nicotine product(s) in the last six months;
  13. Concurrent disease (such as porphyria) or drug(s) (such as methotrexate or chloroquine) known to induce severe photosensitivity of the skin;
  14. Patient has ongoing malignant disease of any type, or any significant chronic disease which, in the opinion of the investigator, might interfere with the evaluation of the study objectives or would result in non-compliance with the study protocol;
  15. Patients with known hypersensitivity to peroxide;
  16. Patients with known photosensitivity or who take drugs to treat photosensitivity.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02325570


Locations
Layout table for location information
Canada, Quebec
Dr. Anthony Seminara Inc.
Montreal, Quebec, Canada, H4X 2E9
Sponsors and Collaborators
KLOX Technologies Inc.
Investigators
Layout table for investigator information
Principal Investigator: Anthony Seminara, DDM Dr. Anthony Seminara Inc.

Layout table for additonal information
Responsible Party: KLOX Technologies Inc.
ClinicalTrials.gov Identifier: NCT02325570     History of Changes
Other Study ID Numbers: CL-K1004-P001
First Posted: December 25, 2014    Key Record Dates
Last Update Posted: February 23, 2016
Last Verified: February 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Periodontitis
Chronic Periodontitis
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases